EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia

Johanne Poisson, Ioanna Daskalaki, Vijay Potluri, Jean-David Morel, Sandra Rodriguez-Lopez, Alessia De Masi, Giorgia Benegiamo, Suresh Jain, Tanes Lima, Johan Auwerx iD

ACS Pharmacology & Translational Science · 2025-01-10 · 8 (1) · 203-215

DOI: 10.1021/acsptsci.4c00587 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2024-12-29. Written by Johanne Poisson and 9 co-authors. Institution: Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne 1015, Switzerland. Cited 8 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: HORIZON EUROPE European Research Council, Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, National Research Foundation of Korea.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The accumulation of ceramides and related metabolites has emerged as a pivotal mechanism contributing to the onset of age-related diseases. However, small molecule inhibitors targeting the ceramide de novo synthesis pathway for clinical use are currently unavailable. We synthesized a safe and orally bioavailable inhibitor, termed ALT-007, targeting the rate-limiting enzyme of ceramide de novo synthesis, serine palmitoyltransferase (SPT). In a mouse model of age-related sarcopenia, ALT-007, administered through the diet, effectively restored muscle mass and function compromised by aging. Mechanistic studies revealed that ALT-007 enhances protein homeostasis in Caenorhabditis elegans and mouse models of aging and age-related diseases, such as sarcopenia and inclusion body myositis (IBM); this effect is mediated by a specific reduction in very-long chain 1-deoxy-sphingolipid species, which accumulate in both muscle and brain tissues of aged mice and in muscle cells from IBM patients. These findings unveil a promising therapeutic avenue for developing safe ceramide inhibitors to address age-related neuromuscular diseases.

Authors and institutions

  • Laboratory of Integrative Systems Physiology, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne 1015, Switzerland.
  • Intonation Research Laboratories, Hyderabad 500076, India.

ORCID profiles: Johan Auwerx

Funding

  • HORIZON EUROPE European Research Council
  • Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
  • National Research Foundation of Korea
  • ?cole Polytechnique F?d?rale de Lausanne

Cite

APA

Poisson, J., Daskalaki, I., Potluri, V., Morel, J. D., Rodriguez-Lopez, S., De Masi, A., Benegiamo, G., Jain, S., Lima, T., & Auwerx, J. (2025). Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia. ACS Pharmacology & Translational Science, 8(1), 203-215. https://doi.org/10.1021/acsptsci.4c00587

Vancouver

Poisson J, Daskalaki I, Potluri V, Morel JD, Rodriguez-Lopez S, De Masi A, et al. Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia. ACS Pharmacology & Translational Science. 2025;8(1):203-215. doi:10.1021/acsptsci.4c00587

BibTeX
@article{Poisson2025,
  author = {Poisson, Johanne and Daskalaki, Ioanna and Potluri, Vijay and Morel, Jean-David and Rodriguez-Lopez, Sandra and De Masi, Alessia and Benegiamo, Giorgia and Jain, Suresh and Lima, Tanes and Auwerx, Johan},
  title = {Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia},
  journal = {ACS Pharmacology & Translational Science},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {203--215},
  doi = {10.1021/acsptsci.4c00587}
}
Start for free →